ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille University), a worldwide leader in γ9δ2 T cells and butyrophilins research, as well as from ...
Oct. 17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy nivolumab to a current treatment regimen.
The final diagnosis was diffuse large B-cell lymphoma (DLBCL) of follicular center origin involving the omentum, bilateral adnexal masses, and left ovary, with gastric implants. A repeat ...